Literatur
-
1
Badesch D B, Tapson V F, McGoon M D, Brundage B H, Rubin L J, Wigley F M, Rich S, Barst R J, Barrett P S, Kral K M, Jobsis M M, Loyd J E, Murali S, Frost A, Girgis R, Bourge R C, Ralph D D, Elliott C G, Hill N S, Langleben D, Schilz R J, McLaughlin V V, Robbins I M, Groves B M, Shapiro S, Medsger T A
Jr.
Continuous intravenous epoprostenol for pulmonary
hypertension due the scleroderma spectrum of disease. A randomized,
controlled trial.
Ann Intern Med.
2000;
132
425-434
-
2
Barst R J, Rubin L J, McGoon M D, Caldwell E J, Long W A, Levy P S.
Survival in primary
pulmonary hypertension with long-term continuous intravenous prostacyclin.
Ann
Intern Med.
1994;
121
409-415
-
3
Barst R J, Rubin L J, Long W A, McGoon M D, Rich S, Badesch D B, Groves B M, Tapson V F, Bourge R C, Brundage B H, Koerner S K, Langleben D, Keller C A, Murali S, Uretsky B F, Clayton L M, Jobsis M M, Blackburn S D Jr, Shortino D, Crow J W. for the Primary Pulmonary Hypertension
Study Group .
A Comparison of Continuous Intravenous
Epoprostenol (Prostacyclin) with Conventional Therapy for Primary
Pulmonary Hypertension.
N Engl J Med.
1996;
334
296-301
-
4
Bartosik I, Eskilsson J, Scheja A, Akesson A.
intermittent iloprost
infusion therapy of pulmonary hypertension in scleroderma-a pilot study.
Br
J Rheumatol.
1996;
35
1187-1188
-
5
Beuckelmann D.
Pulmonale
Hypertonie.
Internist.
1997;
38
1020-1033
-
6
Cremona G, Higenbottam T.
Role of prostacyclin
in the treatment of primary pulmonary hypertension.
Am
J Cardiol.
1995;
75
67A-71A
-
7
Fishman A P.
Epoprostenol
(Prostacyclin) and Pulmonary Hypertension.
Ann Intern
Med.
2000;
132
500-502
-
8
Fuster V, Steele P M, Edwards W D, Gersh B J, McGoon M D, Frye R L.
Primary
pulmonary hypertension: natural history and the importance of thrombosis.
Circulation.
1984;
70
580-587
-
9
Grant S M, Goa K L.
Iloprost.
Drugs.
1992;
43
889-924
-
10
Grimminger F, Rose F, Ghofrani H A, Schermuly R T, Weissmann N, Olschewski H, Walmrath D, Seeger W.
Inhalative Strategien
zur Verbesserung der pulmonalen Hämodynamik und des Gasaustausches
bei Sepsis und schwerer pulmonaler Hypertonie.
Z Kardiol.
2000;
89
477-484
-
11 Prostacyclin and its stable
analogue iloprost. Gryglewski RJ, Stock G (Eds.) Springer
Verlag 1987
-
12
Higenbottam T W, Spiegelhalter D, Scott J P, Fuster V, Dinh-Xuan A T, Caine N, Wallwork J.
Prostacyclin
(epoprostenol) and heart-lung transplantation as treatments for
severe pulmonary hypertension.
Br Heart J.
1993;
70
366-370
-
13
Higenbottam T, Butt A Y, McMahon A, Westerbeck R, Sharples L.
Long-term
intravenous prostaglandin (epoprostenol or iloprost) treatment of
severe pulmonary hypertension.
Heart.
1998;
80
151-155
-
14
Higenbottam T W, Butt A Y, Dinh-Xaun A T, Takao M, Cremona G, Akamine S.
Treatment of pulmonary
hypertension with the continuous infusion of a prostacyclin analogue,
iloprost.
Heart.
1998;
79
175-179
-
15
Higenbottam T, Marriott H, Siddons T, Smith A PL.
Primary and
secondary pulmonary hypertension.
Semin Resp Crit Care
Med.
1998;
19
91-95
-
16
Höper M M, Olschewski H, Ghofrani H A, Wilkens H, Winkler J, Borst M M, Niedermeyer J, Fabel H, Seeger W. and the German PPH Study Group .
A comparison of the acute
hemodynamic effects of inhaled nitric oxide and aerosolized iloprost
in primary pulmonary hypertension.
J Am Coll Cardiol.
2000;
35
176-182
-
17
Höper M M, Schwarze M, Ehlerding S, Adler-Schürmeyer A, Spiekerkötter E, Niedermeyer J, Hamm M, Fabel H.
Long-term treatment of
primary pulmonary hypertension with aerosolized iloprost, a prostacyclin
analogue.
N Engl J Med.
2000;
342
1866-1870
-
18
Humbert M, Sanchez O, Fartoukh M, Jagot J L, Le G all
C, Sitbon O, Parent F, Simonneau G.
Short-term and long-term
epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary
to connective tissue diseases: results of a pilot study.
Eur
Respir J.
1999;
13
1351-1356
-
19
Jones D K, Higenbottam T W, Wallwork J.
Treatment
of primary pulmonary hypertension with intravenous epoprostenol
(prostacyclin).
Br Heart J.
1987;
57
270-278
-
20
Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H.
Hemodynamic effects
of iloprost, a prostacyclin analog.
Clin Pharmacol Ther.
1984;
36
464-469
-
21
Klings E S, Hill N S, Ieong M H, Simms R W, Korn J H, Farber H W.
Systemic sclerosis-associated
pulmonary hypertension: short-long-term effects of epoprostenol
(prostacyclin).
Arthritis Rheum.
1999;
42
2638-2645
-
22
Krause W, Krais T.
Pharmacokinetics and pharmacodynamics
of the prostacyclin analogue iloprost in man.
Eur J Clin
Pharmacol.
1986;
30
61-68
-
23
Kyle M V, Belcher G, Hazleman B L.
Placebo
controlled study showing therapeutic benefit of iloprost in the
treatment of Raynaud¿s phenomenon.
J Rheumatol.
1992;
19
1403-1406
-
24
McLaughlin V V, Genther D E, Panella M M, Rich S.
Reduction in pulmonary
vascular resistance with long-term epoprostenol (prostacyclin) therapy
in primary pulmonary hypertension.
N Engl J Med.
1998;
338
273-277
-
25
McLaughlin V V, Genthner D E, Panella M M, Hess D M, Rich S.
Compassionate
use of continuous prostacyclin in the management of secondary pulmonary
hypertension: A case series.
Ann Intern Med.
1999;
130
740-743
-
26
Menon N, McAlpine L, Peacock A J, Madhok R.
The
acute effects of prostacyclin on pulmonary hemodynamics in patients
with pulmonary hypertension secondary to systemic sclerosis.
Arthritis Rheum.
1998;
41
466-469
-
27
Mikhail G, Gibbs J, Richardson M, Wright G, Khaghani A, Banner N, Yacoub M.
An
evaluation of nebulized prostacyclin in patients with primary and
secondary pulmonary hypertension.
Eur Heart J.
1997;
18
1499-1504
-
28
Nocturnal Oxygen
Therapy Trial Group .
Continous or nocturnal oxygen
therapy in hypoxemic chronic obstructive lung disease: a clinical
trial.
Ann Intern Med.
1980;
93
391-398
-
29
Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S.
Comparative
acute effects of adenosine and prostacyclin in primary pulmonary
hypertension.
Chest.
1995;
107
54-57
-
30
Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W.
Aerosolized prostacyclin
and iloprost in severe pulmonary hypertension.
Ann Intern
Med.
1996;
124
820-824
-
31
Olschewski H, Ghofrani H A, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, Seeger W.
Inhaled
prostacyclin and iloprost in severe pulmonary hypertension secondary
to lung fibrosis.
Am J Respir Crit Care Med.
1999;
160
600-607
-
32
Olschewski H, Ghofrani H A, Schmehl T, Winkler J, Wilkens H, Höper M M, Behr J, Kleber F X, Seeger W. German PPH Study Group .
Inhaled iloprost to treat
severe pulmonary hypertension. An uncontrolled trial.
Ann
Intern Med.
2000;
132
435-443
-
33
Rich S, Kaufmann E, Levy P S.
The effect of
high dosis of calcium-channel blockers on survival in primary pulmonary
hypertension.
N Engl J Med.
1992;
327
76-81
-
34
Rich S.
Medical
treatment of primary pulmonary hypertension: a bridge to transplantation?.
Am
J Cardiol.
1995;
75
63A-66A
-
35
Rich S, McLaughlin V V.
The
effects of chronic prostacyclin therapy on cardiac output and symptoms
in primary pulmonary hypertension.
J Am Coll Cardiol.
1999;
34
1184-1187
(4)
-
36
Rubin L J, Groves B M, Reeves J T, Frosolono M, Handel F.
Prostacyclin-induced
acute pulmonary vasodilation in primary pulmonary hypertension.
Circ.
1982;
66
334-338
-
37
Rubin L J, Mendoza J, Hood M, McGoon M, Barst R, Williams W B, Diehl J H, Crow J, Long W.
Treatment of primary pulmonary
hypertension with continuous intravenous (epoprostenol). Results
of a randomized trial.
Ann Intern Med.
1990;
112
485-491
-
38 Rubin L J. Pulmonary
Vasculitis and Primary Pulmonary Hypertension. WB Saunders,
Philadelphia In: Textbook of Respiratory Medicine.
3. ed.: Nadel JF, Murray JA, Mason RJ, Boushey HA 2000: 1442-1452
-
39
Scott J P, Higenbottam T, Wallwork J.
The
acute effect of the synthetic prostacyclin analogue iloprost in
primary pulmonary hypertension.
Br J Clin Pract.
1990;
44
231-234
-
40
Shapiro S M, Oudiz R J, Cao T, Romano M A, Beckmann X J, Georgiou D, Mandayam S, Ginzton L E, Brundage B H.
Primary
pulmonary hypertension: improved long-term effects and with continuous
intravenous epoprostenol infusion.
J Am Coll Cardiol.
1997;
30
343-349
-
41
Sitbon O, Brenot F, Denjean A, Bergeron A, Parent F, Azarian R, Herve P, Raffestin B, Simonneau G.
Inhaled
nitric oxide as a screening vasodilator agent in primary pulmonary
hypertension.
Am J Respir Crit Care Med.
1995;
151
384-389
-
42
Stricker H, Domenighetti G, Fiori G, Mombelli G.
Sustained improvement
of performance and haemodynamics with long-term aerosolised prostacyclin
therapy in severe pulmonary hypertension.
Schweiz Med
Wochenschr.
1999;
129
923-927
-
43
Stuart-Harris S C, Flenley D C, Bishof J M.
Long
term domiciliary oxygen therapy in chronic hypoxic cor pulmonale
complicating chronic bronchitis and emphysema: a report of the Medical
Research Council Working Party.
Lancet.
1981;
1
681-686
-
44
Vane J R, Botting R M.
Pharmacodynamic
profile of prostacyclin.
Am J Cardiol.
1995;
75
3A-10A
-
45
Wax D, Garofano R, Barst R J.
Effects of long-term
infusion of prostacyclin on exercise performance in patients with
primary pulmonary hypertension.
Chest.
1999;
116
914-920
-
46
Wensel R, Opitz C F, Ewert R, Bruch L, Kleber F X.
Effects
of iloprost inhalation on exercise capacity and ventilatory efficiency
in patients with primary pulmonary hypertension.
Circulation.
2000;
101
2388-2392
-
47
Wigley F M, Wise R A, Seibold J R, McCloskey D A, Kujala G, Medsger T A, Stehen V D, Varga J, Jiminez S, Mayes M, Clements P J, Weiner S R, Porter J, Ellman M, Wise C, Kaufman L D, Williams J, Dole W.
Intravenous
iloprost infusion in patients with Raynaud Phenomenon secondary
to Systemic Sclerosis. A multicenter, placebo-controlled, double-blind
study.
Ann Int Med.
1994;
120
199-206
Korrespondenz
Privatdozent Dr. med. K. Waßermann
Arbeitsgruppe Pneumologie Klinik III für
Innere Medizin Universität zu Köln
Joseph Stelzmann Straße 9
50922 Köln
Telefon: 0221/478-4432
Fax: 0221/478-3137
eMail: aip04@uni-koeln.de
